

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA



## **Cosmo announces R&D day in Zurich for Investors and Analysts**

**Dublin – October 24, 2016** Cosmo Pharmaceuticals NV. (SIX: COPN) will present to its shareholders, analysts and the financial press a comprehensive update on the results of the phase III clinical trials of LuMeBlue™ and Rifamycin and the consequent strategy at its R&D Day to be held November 29, starting at 15:00 CET at the Sonnenberg Convention Center in Zurich.

After the presentation there will be a stand-up dinner which is scheduled to end at 21:00.

For all those not able to attend, presentations will be available online on November 29, 2016 on <http://www.cosmopharma.com/ir/presentation.aspx>

### **About Cosmo Pharmaceuticals**

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In addition, the Company has developed a medical device for polyp and adenoma excision and is developing a diagnostic for the detection of colon cancer as well as a new chemical entities that are being developed by the associate company Cassiopea S.p.A. for the topical treatment of skin diseases. Cosmo's MMX® products that have reached the market are Lialda®/Mezavant®/MesavancoI®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Salix/Valeant and in the Rest of the World to Ferring as Cortiment®. Cosmo's proprietary MMX® technology is at the core of the Company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company's website: [www.cosmopharma.com](http://www.cosmopharma.com)

### **Next events**

Jefferies Global Healthcare Conference	16 November 2016 in London
Credit Suisse Mid Cap Conference	17.-18. November 2016 in Zürich
Full-year results 2016 reporting	March 2017
Annual General Meeting	April 2017

**Contact:**

Dr. Chris Tanner, Head of Investor Relations

Cosmo Pharmaceuticals NV

Tel: +352 2784 87 49

[ctanner@cosmopharma.com](mailto:ctanner@cosmopharma.com)

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ m

###